Is Crispr Therapeutics Stock Grossly Overvalued? [The Motley Fool]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: The Motley Fool
Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity? Despite a wave of bad news for gene-editing companies employing the CRISPR/Cas 9 system as of late, shares of Crispr Therapeutics ( NASDAQ:CRSP ) have performed remarkably well this year. At the time of writing, for example, Crispr's stock has exactly doubled in value since the start of the year. While the biotech's shares are well off of their 52-week highs, Crispr's current $2.2 billion market capitalization might still be overly stretched. Thanks to a clinical hold on the biotech's autologous gene-edited hematopoietic stem cell therapy CTX-001 by the Food and Drug Administration (FDA) last May, Crispr remains a highly speculative pre-clinical venture at this point in time. In fact, the biotech's marked decline over the past month (down 25.9% since July 9) might be a sign that Mr. Market has recognized
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Crispr Therapeutics: Now Is The Time To Buy [Seeking Alpha]Seeking Alpha
- Aspen Ideas: Health Announces Global Health Experts to Speak at Annual Summit [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why [Yahoo! Finance]Yahoo! Finance
- Capsida Biotherapeutics to Present New Data on its Wholly Owned Gene Therapy Programs in Genetic Epilepsy and Parkinson's Disease at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/21/24 - Beat
CRSP
Sec Filings
- 4/17/24 - Form 4
- 4/15/24 - Form 144
- 4/10/24 - Form SC
- CRSP's page on the SEC website